Hanaa Siddiqi

Biosimilars recently have made significant strides toward greater acceptance and utilization since their first U.S. approval in 2015, although challenges persist.

As part of an analysis for Sanofi U.S., we examine the economic implications of kidney transplants, including hospital expense and Medicare allowed costs.

How current Part D risk scores could interact with point-of-sale rebates.